Core Viewpoint - The article discusses the resurgence of COVID-19 cases in China, highlighting the increasing positivity rates and the need for continued vigilance, especially among high-risk populations [4][5][9]. Summary by Sections COVID-19 Resurgence - COVID-19 has become the leading pathogen in emergency visits across most regions in China, with positivity rates rising from 7.5% to 16.2% between late March and early May 2025 [5][6]. - The current wave of infections is attributed to a decline in population immunity, as the last peak occurred over six months ago [9]. Expert Opinions - Experts suggest that while the current strains are less virulent, high-risk groups, including the elderly and those with underlying health conditions, should remain cautious and take preventive measures [7][9]. - The article emphasizes the importance of vaccination and protective behaviors, especially for vulnerable populations [7][20]. Regional Differences - The article notes a temporal difference in the spread of COVID-19 between northern and southern China, with the south approaching its peak later than the north [10][11]. - Data indicates that southern provinces have a slightly higher positivity rate compared to northern provinces during this wave [10]. Variants and Symptoms - The main circulating variants are XDV and NB.1.8.1, both of which belong to the Omicron family and exhibit immune evasion capabilities [13][15]. - Symptoms of the current infections are generally mild but can lead to severe outcomes in high-risk individuals, with prolonged cough and other respiratory issues being common [15][19]. Vaccination Strategies - The article outlines the latest COVID-19 vaccines available in China, which include formulations targeting the XBB variant [24][26]. - Vaccination remains the best preventive measure, with studies showing significant reductions in hospitalization risks for vaccinated individuals [23][27]. Treatment Options - A variety of antiviral medications are available for COVID-19 treatment, with specific recommendations for high-risk patients [34][35]. - The article stresses the importance of using antiviral drugs judiciously, particularly for non-severe cases [35][36].

Group 1 - The core incident revolves around the false rumor of Eason Chan's death due to COVID-19 complications, which sparked widespread discussion online [6][10][19] - The rumor originated from a YouTube account "台山TV" that falsely claimed Eason had died on May 16, 2025, and had previously spread similar false news about other celebrities [19][20] - Eason Chan's team initially chose to remain silent on the rumors to avoid giving them more attention, but eventually, he addressed the situation through an Instagram post on May 19, humorously indicating his recovery [22][26] Group 2 - The public reaction included a mix of concern and skepticism, with many fans expressing relief after Eason's confirmation of his well-being, while some questioned the lack of direct video evidence [30] - The incident highlighted the need for better regulation of AI-generated misinformation and the impact of such rumors on public figures and their families [30] - Eason's health status was confirmed to be stable, and he had postponed his concert in Kaohsiung due to COVID-19, with plans to resume activities shortly [26][29]

Group 1 - The recent COVID-19 outbreak, highlighted by the diagnosis of singer Eason Chan, has led to a significant increase in demand for antiviral medications and online consultations, with antiviral drug sales on JD.com increasing by 700% year-on-year and 75% month-on-month [1] - JD Health's online hospital has reported a 20% week-on-week increase in COVID-19 related consultations, indicating a rising public concern regarding respiratory infections [1] - JD Health provides 24/7 services for patients, allowing them to access professional medical consultations and medication guidance through the JD app [1] Group 2 - JD.com has ensured a sufficient inventory of respiratory pathogen-related medications, including seven preferred antiviral drugs specifically for COVID-19, such as Molnupiravir and Nirmatrelvir/Ritonavir [2] - To alleviate patient burdens, JD Health has reduced prices on certain antiviral medications, including a 20 yuan decrease on a combination pack of Nirmatrelvir and Ritonavir [2] - JD Health has also launched China's first self-developed influenza-specific drug, Isodax, which has shown to significantly shorten the duration of flu symptoms with a single dose [2] Group 3 - Medical professionals recommend that the public maintain hygiene practices, such as regular handwashing and wearing masks, and seek medical attention promptly if experiencing severe symptoms [3] - Special populations, including the elderly and pregnant women, are advised to monitor their blood oxygen levels to prevent dangerous situations due to hypoxia [3]